# Donor cells, less chemotherapy: early promise for autoimmune disease

By Alyse Gonthier, PhD, Zack Holland · Published November 19, 2026

Canonical: https://www.katalyzeai.com/newsletter/donor-cells-less-chemotherapy-early-promise-for-autoimmune-disease

## Contents

- [Welcome to Highly Regulated 010, from Katalyze](https://www.katalyzeai.com/newsletter/donor-cells-less-chemotherapy-early-promise-for-autoimmune-disease#welcome-to-highly-regulated-010-from-katalyze)
- [Worth Your Time](https://www.katalyzeai.com/newsletter/donor-cells-less-chemotherapy-early-promise-for-autoimmune-disease#worth-your-time)
- [Meanwhile, at Katalyze](https://www.katalyzeai.com/newsletter/donor-cells-less-chemotherapy-early-promise-for-autoimmune-disease#meanwhile-at-katalyze)
- [The Feature: From one donor to many patients: the next step for cell therapy](https://www.katalyzeai.com/newsletter/donor-cells-less-chemotherapy-early-promise-for-autoimmune-disease#the-feature-from-one-donor-to-many-patients-the-next-step-fo)
- [Something Good](https://www.katalyzeai.com/newsletter/donor-cells-less-chemotherapy-early-promise-for-autoimmune-disease#something-good)

![](https://media.beehiiv.com/uploads/asset/file/e933d93d-5c43-4ca1-8ffd-2c321c8ccc78/Edition_010_header___1200_600_for_Beehiiv_1x.png)

## Welcome to Highly Regulated 010, from Katalyze

Welcome back to Highly Regulated. Last week, we[ followed cancer vaccines](https://www.katalyzeai.com/newsletter/what-are-cancer-vaccines-and-why-are-they-making-headlines) from a nineteenth-century surgeon's bacterial injections to a Phase 3 melanoma trial. That vaccine is designed for one person and made to order, helping the immune system recognize the unique features of their tumor.

This week, the opposite approach: **cell therapies made from one healthy donor's cells rather than each patient's own**, so more patients get treated faster. Earlier this month, an investigational donor-derived therapy reported promising first clinical results in autoimmune disease. We'll trace the development that led there and the manufacturing that would carry it forward.

We'll end with Something Good: an infant returns home after an experimental treatment stops his relentless seizures.

First, a few things worth your attention from around the industry.

[Alyse Gonthier, PhD](https://www.linkedin.com/in/gonthieralyse/) and [Zack Holland](https://www.linkedin.com/in/zackholland/) from Katalyze

## Worth Your Time

- **Neurosterix raises $105 million Series B for more selective neuropsychiatric drugs. **Treating schizophrenia can mean balancing symptom control against difficult side effects. Neurosterix is developing compounds that bind a receptor away from the main binding site and adjust its response, an approach called allosteric modulation. On November 11, Addex, which spun out Neurosterix in 2024, announced that the company had closed a $105 million Series B. The proceeds will primarily support a planned Phase 2 trial and the broader neuropsychiatric pipeline. The aim is to reduce psychosis with fewer movement and metabolic side effects than traditional dopamine-blocking drugs. [Neurosterix's Series B](https://www.addextherapeutics.com/en/investors/ad-hoc-announcements-art-53-lr/addex-spin-out-neurosterix-closes-105-million-series-b-financing/)
- **A freezing study preserves therapeutic immune cell function with less DMSO. **Freezing cells makes storage and shipping easier, but the cells still need to function after thawing. Researchers at Charité and partner institutions studied immune cells that help restrain excessive immune responses (regulatory T cells), manufactured under clinical quality standards. Their paper compared a common freezing protectant, dimethyl sulfoxide (DMSO), at concentrations of 10% and 5%. In matched laboratory comparisons, the 5% version preserved key measures of cell identity and immune-suppressing function immediately after thawing and at 24 hours. For the intended treatment, thawed cells would be infused without washing out the DMSO, which itself can cause dose-related side effects on the heart and nervous system. Using less could reduce patients' exposure while preserving the cells' therapeutic function. [Preserving Regulatory T Cells After Freezing](https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2026.1961610/full)

![Half the solvent into the patient, less risk. Reducing DMSO percentage while maintaining cell function.](https://media.beehiiv.com/uploads/asset/file/8e8ff900-6ab5-478c-a0a0-8e4761cf49dd/Fig._01___Worth_Your_Time___Reducing_reaction_risk_in_patients_with_less_DMSO_1x.png)

- **Lonza agrees to expand its U.S. manufacturing network from four sites to nine. **Developers of complex medicines need specialized manufacturing capacity close to their clinical and commercial operations. Lonza agreed to acquire five U.S. contract development and manufacturing sites and their associated businesses from Merck KGaA (Germany), bringing approximately 1,100 employees into its network. The sites add capabilities in linking drugs to antibodies, making viral vectors, and formulating advanced drug-delivery products. The purchase more than doubles Lonza's U.S. manufacturing footprint and adds U.S. capabilities in bioconjugation and the potent drugs and linkers used in antibody-drug conjugates. [Lonza's U.S. Expansion](https://www.lonza.com/news/2026-11-03-07-00)
- **Novartis is hiring an executive director to turn one-off AI models into shared systems. **Many teams can build a working AI model and then struggle to run it, monitor it, and reuse it elsewhere. Novartis is recruiting an Executive Director, Data Science and Applied AI, to lead its commercial AI work and move it from individual models toward systems the whole organization can maintain. The role covers machine learning for customer engagement and patient identification; the engineering practices that keep models running and monitored in production; and governance covering responsible AI, data privacy, and regulatory compliance. [Novartis's Data Science and AI Opening](https://www.novartis.com/careers/career-search/job/details/req-10092235-executive-director-data-science-applied-ai)
- **T-Therapeutics raises $133 million Series B to take two programs into the clinic. **Many potential drug targets are inside cells, beyond the direct reach of antibodies. T-Therapeutics engineers T cell receptors to recognize fragments of those internal proteins displayed on the cell surface, then pairs them with an arm that recruits T cells to attack. On November 5, they closed a $133 million Series B, co-led by Advent Life Sciences and the British Business Bank, with Johnson & Johnson, Eli Lilly, Merck KGaA's M Ventures, and Samsara BioCapital joining as new investors. The funding is intended to take two lead programs, in cancer and autoimmune disease, into clinical trials and through clinical proof of concept. [T-Therapeutics' Series B](https://www.cic.vc/t-therapeutics-announces-oversubscribed-133-million-series-b-financing-to-achieve-clinical-proof-of-concept-for-first-in-class-tcr-bispecific-therapies-in-cancer-and-autoimmune-disease/)

## Meanwhile, at Katalyze

### Everything you need to know about AI in Pharma heading into next year, in one report

Our latest report looks at the opportunities for AI in pharma, with a focus on manufacturing and quality. It explores the current regulatory requirements and guidance, applications like deviation investigations and yield improvement, and the evidence teams need to evaluate these use cases.

The report is free, and you can request a copy [here](https://www.katalyzeai.com/reports/state-of-ai-in-pharma-2027). If you're working out where AI fits in regulated manufacturing work, we'd like to get your thoughts.

![Report: The State of AI in Pharma, 2027](https://media.beehiiv.com/uploads/asset/file/421c80c8-a76f-4fa5-82ce-e4e883b15cb5/Fig._02___Meanwhile__at_Katalyze__The_State_of_AI_in_Pharma_for_2027__1x.png)

## The Feature: From one donor to many patients: the next step for cell therapy

Engineering immune cells to recognize disease targets opened a new way to make medicine. The next challenge is getting those treatments to more people. Donor-derived therapies could help by allowing treatment to be manufactured in advance, instead of starting a new run for each patient.

### From engineered receptors to individual batches

In 1989, researchers showed they could engineer immune cells called T cells to recognize a chosen target. The team, Gideon Gross, Tova Waks, and Zelig Eshhar, built a receptor by joining two components: an antibody part that recognized the target and parts of a T cell receptor that could pass the signal into the cell. In the lab, T cells carrying these receptors recognized and responded to their targets. This work helped lay the foundation for chimeric antigen receptor T cells, now known as CAR-T cells. [An Early Engineered T Cell Receptor](https://www.pnas.org/doi/pdf/10.1073/pnas.86.24.10024)

In 2015, two infants with aggressive leukemia received gene-edited CAR-T cells from a healthy donor. The first patient, Layla Richards, was one year old and out of standard treatment options. Results published by Waseem Qasim and colleagues in 2017 reported molecular remission within 28 days in both children, allowing them to proceed to stem cell transplantation. Donor cells had offered a bridge to transplant. [Early Donor-Cell Treatment in Infants](https://discovery.ucl.ac.uk/id/eprint/1538479/1/QASIM%20aaj2013_final%20OA%20wq.pdf)

![37 years of engineered cell therapy. 1989, 2015, 2017, 2026.](https://media.beehiiv.com/uploads/asset/file/c6186da9-1e3e-4db9-84cd-9ca291d4a7cb/Fig._03___How_engineered_cell_therapy_developed_1x.png)

In 2017, the FDA approved the first CAR-T cell therapy, made from a patient's own T cells genetically modified to recognize and attack cancer. Using the patient's own cells, an autologous approach, helps avoid immune rejection. Clinicians collect white blood cells, then send them to a facility where T cells are engineered, grown, tested, and prepared for return to the patient. [How CAR-T Cells Are Made](https://www.cancer.gov/about-cancer/treatment/research/car-t-cells)

That process can take several weeks. Earlier treatment and the disease itself can affect the number and quality of cells collected, so each run starts with different material, often while the patient's condition is changing.

Testing and documentation must follow each batch separately. Even with an efficient shared process, a novel product must be made and released for every patient. [FDA Considerations for CAR-T Cell Products](https://www.fda.gov/media/156896/download)

### One donor opens the door to many patients

Using another person's cells makes the therapy allogeneic. Cells can be engineered, expanded, and stored before a patient needs them. Allogene Therapeutics says one manufacturing run could eventually supply treatment for a hundred or more patients at scale. [Allogene on Manufacturing Scale](https://allogene.com/science/)

With doses in stock, patients could avoid waiting for their own manufacturing run. Teams could also complete batch testing before treatment is needed, making production and quality control less dependent on an individual patient's timetable.

![Each patient their own donor, or one donor for a hundred.](https://media.beehiiv.com/uploads/asset/file/95f5a9a0-bf22-4f1e-bc58-38050bd55e71/Fig._04___Each_patient_their_own_donor__or_one_donor_for_a_hundred_1x.png)

Donor cells bring a biological challenge: the patient's immune system can reject them, while donor T cells can attack the patient's tissues, causing graft-versus-host disease. Gene editing and other strategies aim to reduce those risks. Many CAR-T regimens also use chemotherapy to reduce immune cells called lymphocytes before infusion, a step called lymphodepletion. Allogene aims to reduce or eliminate that preparation. [Allogene's Anti-Rejection Strategy](https://allogene.com/science/)

### Encouraging first results in autoimmune disease

On November 9, Allogene presented the first clinical results from its Phase 1 RESOLUTION trial of their ALLO-329 product at the American College of Rheumatology meeting in Orlando. It carries two CARs: one targets a protein called CD19 on B cells involved in autoimmune disease; the other targets CD70 on activated T cells, including those reacting against donor cells. This second receptor is designed to help the therapy resist rejection. [How ALLO-329 Is Designed](https://allogene.com/wp-content/uploads/2026/10/Zhang_ACR-2024_ALLO-329-Preclinical-ACR-Poster_Final-for-upload_17Oct24-1.pdf)

![One arm treats the disease, the other buys time.](https://media.beehiiv.com/uploads/asset/file/80ecca31-b7db-4adc-90e0-0f772cc9a39c/Fig._05___Why_the_therapy_has_two_targeting_arms_1x.png)

As of the September 21st data cutoff, 18 patients have received treatment. They had either systemic sclerosis, which can thicken skin and damage internal organs; inflammatory muscle diseases called idiopathic inflammatory myopathies; or lupus. The initial efficacy analysis focused on 10 patients whose systemic sclerosis substantially affected their skin. [Allogene's First Clinical Results](https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-reports-first-clinical-data-phase-1)

Eight of those 10 achieved and maintained an improvement of at least five points on a measure of skin thickening, called the modified Rodnan skin score. Patients stopped background immunosuppressants before treatment as required by the study; nine remained off them at the cutoff, with the longest interval exceeding eight months. The possibility of sustained improvement with less ongoing treatment is an encouraging start.

These findings come from a small, uncontrolled Phase 1 study, and skin-score improvements don't by themselves establish reversal of internal-organ disease. The program is now built to run the larger studies, with longer follow-up, that would settle how durable the benefit is.

![The first results for off-the-shelf donor cells.](https://media.beehiiv.com/uploads/asset/file/40985a60-35c9-42fa-976c-db1d54cf1084/Fig._06___The_first_results_for_off-the-shelf_donor_cells_1x.png)

### Testing treatment without preparatory chemotherapy

The study is also exploring whether patients could receive donor cells with less demanding preparation.

RESOLUTION is testing three regimens: six patients received no lymphodepleting chemotherapy, nine received one chemotherapeutic, and three received a combination of two chemotherapeutics. Skin-score improvements were reported across all three approaches.

The early safety findings are encouraging, too. No dose-limiting toxicities or graft-versus-host disease were reported across the 18 patients. Four had cytokine release syndrome, an inflammatory reaction following immune-cell therapy: three cases were grade 1 and one was grade 2. [RESOLUTION's Regimens and Safety Data](https://allogene.com/wp-content/uploads/2026/11/1262049_ACR2026_Allo-329-Expedited-Poster_90W-x-42H-in_PRINT_Corrected_09Nov2026.pdf)

The groups are currently too small to establish comparative safety, but clinical activity without preparatory chemotherapy supports further testing of a potentially less burdensome approach.

That's the part of this readout I keep returning to. If larger studies confirm durable benefit without lymphodepletion, patients could avoid the added burden of chemotherapy entirely. Combining treatment made in advance with simpler preparation could make cell therapy more practical for people living with chronic autoimmune disease.

![Cell therapy without the chemotherapy that comes first.](https://media.beehiiv.com/uploads/asset/file/1cb34ba3-83ca-4a97-9259-3b87e8c41639/Fig._07___Cell_therapy_without_the_chemotherapy_that_comes_first_1x.png)

### What comes next

Allogene is continuing dose escalation to select a Phase 2 regimen, with another readout planned for 2027. The next results will help show how long improvements last and who benefits most. Consistent batch quality and reliable storage will also matter as development advances toward broader use. [Allogene's RESOLUTION Next Steps](https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-reports-first-clinical-data-phase-1)

Decades of work have brought engineered donor cells into clinical trials. Now we need to turn that early promise into reliable treatments that are ready right when patients need them.

## Something Good

### From 110 seizures a day to zero and a return home

Adnan's seizures began in his first days of life. Seven treatment approaches failed to bring them under control, and he was experiencing around 110 a day.

Genetic testing gave his doctors in Dubai a new direction. They identified the cause of his rare epilepsy and secured access to an experimental oral medicine designed to address the abnormal activity involved. The hospital and health authorities worked together to bring the treatment to him, without his family having to travel abroad.

![From 110 seizures a day to none.](https://media.beehiiv.com/uploads/asset/file/f1c99a17-457e-499b-98ab-fe1beac25e23/Something_Good___010__From_110_seizures_a_day_to_none__1x.png)

According to his treating team, his seizures stopped within 30 minutes of the first dose. He went home a week later. In a November 2 report, the hospital said he remained seizure-free and was making progress in growth and development. [Infant Responds to Experimental Epilepsy Treatment](https://www.wam.ae/en/article/c31xcde-dubai-medical-team-stops-severe-epileptic-seizures)

This is one child's experience with a treatment still under investigation, and his doctors continue to monitor him closely. For Adnan and his family, though, life has already changed: after months of relentless seizures, they are home together.

The Katalyze Marketing Team
